Merck Patent Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft MIT

Merck Patent Gesellschaft

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Biomet Deutchland Gmbh

Merck Patent Department

Alfred Jonczyk

Horst Kessler

Guenter Hoelzemann

Frank Zenke

Simon Lawrence Goodman

Christiane Amendt

Gunter Holzemann

Dieter Dorsch

Beate Diefenbach

Wilfried Rautenberg

Wolfgang Staehle

Brunhilde Felding-Habermann

Oliver Schadt

Peter Raddatz

Claus J Schmitges

Helene Crassier

Friedrich Rippmann

Jochen Wermuth

Berthold Nies

Martin Kantlehner

Roland Haubner

Dirk Finsinger

Hans-Peter Buchstaller

Guido Melzer

Klaus Otto Minck

Karl-August Ackermann

Johannes Sombroek

Mireille Krier

Jaume Adan

Arne Sutter

Elisabet Rosell-Vives

Klaus-Otto Minck

Frank Stieber

Joachim Gante

Hartmut Greiner

Timo Heinrich

David A Cheresh

Marcus Koppitz

Lars Thore Burgdorf

Hans-Eckart Radunz

Christoph Saal

Clemens Kuehn

Gunther Zischinsky

Michael Lange

Francesc Mitjans

Soheila Anzali

Gerald Scholz

Jutta Haunschild

G&uuml;nter H&ouml;lzemann

J&ouml;rg Simon Schmitt

Wolfgang St&auml;hle

Jörg Meyer

Kerstin Seemann

Soenke Petersen

Harald Untenecker

J&ouml;rg Meyer

Marion Gurrath

Gerhard Muller

Renate Naumann

Michael Dechantsreiter

Thorsten Knoechel

Holger Enderle

Wolfgang Stähle

Ulrich Groth

Gunter H&ouml;lzemann

Gema Tarrason

Claudia Cases

Marta Soler Riera

Markus Arnold

Sigrid R&ouml;sener

Astrid Perschl

Simon Goodmann

Wolgang Stähle

The invention relates generally to cyclic peptides and their use in compositions, especially topical, cosmetic and/or personal care compositions, and compositions containing said cyclic peptides.

Compositions containing cyclic peptides and methods of use

Compounds of the formula I in which W, R, Rand Rhave the meanings indicated in claim, are inhibitors of ALK1, AL2 and ALK5, and can be employed for the treatment of diseases such as cancer.

3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives

The compound 4-(2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2,7-naphthyridin-1-ylamine and pharmaceutically usable salts and/or tautomers thereof. The use of this compound for the treatment of tumors, tumor growth, tumor metastases and/or AIDS.

7-azaindole-2,7-naphthyridine derivative for the treatment of tumours

The present invention relates to novel bipyridyl derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

Bipyridyl derivatives

The present invention relates to novel pyrido[2,3-b]pyrazine compounds of formula (I): and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith

Novel hetarylaminoquinoline derivatives of formula (I) wherein X, Z, Het, R1, R2, R3 and R4 have the meaning according to claim, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.

Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors

Novel hetaryl-[1,8]naphthyridine derivatives of formula (I) wherein R1, R2, W, W, Wand Whave the meaning according to claim, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.

Hetaryl-[1,8]naphthyridine derivatives

Compounds of the formula (I), in which R, X, Y, Z, Rand Rhave the meanings indicated in claim, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours. 

Pyrrolidone derivatives for use as MetAP-2 inhibitors

Novel hetarylaminonaphthyridine derivatives of formula (I) wherein X, R1, R2, R3, R4, W1, W2, W3, W5 and W6 have the meaning according to claim, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.

Hetarylaminonaphthyridines

The present invention relates to novel [1,8]naphthyridine derivatives of formula (I) and to the use of such compounds in which the inhibition, regulation and/or modulation of signal transduction by ATP consuming proteins like kinases plays a role, particularly to inhibitors of TGF-beta receptor kinases, and to the use of such compounds for the treatment of kinase-induced diseases, in particular for the treatment of tumors.

2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer

The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals.

Solid materials of {[(2S,5R,8S,11S)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them

The invention relates to compounds of formula 1, the production and use thereof as a medicament for the treatment of diseases, particularly tumours and/or diseases caused, mediated or propagated by angiogenesis. The compounds of formula 1 are effective inhibitors of tyrosin kinases, particularly TIE-2 and VEGFR, and Raf-kinases. (I) 

1,3-benzoxazolyl derivatives as kinase inhibitors

The present invention relates to heterocyclic substituted bisarylurea derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. 

Heterocyclic substituted bisarylurea derivatives

Growing community of inventors

Darmstadt, Germany

Alfred Jonczyk